Bio-Rad Laboratories, Inc. Class A Common Stock vs JetBlue Airways Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while JetBlue Airways Corporation trades at $5.81 (market cap $2.19B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 4.3× JetBlue Airways Corporation's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| BIO | JBLU | |
|---|---|---|
Market Cap | $9.43B | $2.19B |
Sector | Health | Industrials |
52-Week High | $356.25 | $6.46 |
52-Week Low | $241.71 | $4.03 |
Enterprise Value | $9.18B | $9.56B |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →